Literature DB >> 9177283

Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase.

M R Smith1, M L Wilson, R Hamanaka, D Chase, H Kung, D L Longo, D K Ferris.   

Abstract

Polo-like kinase (Plk) is the mammalian homologue of the Drosophila polo and Saccharomyces cerevisiae CDC5 genes, which are thought to be involved in regulating chromosomal segregation. Previously, we showed that transient ectopic expression of Plk could induce DNA synthesis in quiescent NIH 3T3 cells, suggesting that Plk might also have a function during G1 or S phase. Here we report that microinjection of Plk mRNA is sufficient to drive quiescent cells into mitosis and that constitutive expression of Plk in NIH 3T3 cells causes oncogenic focus formation. These transformed cells grow in soft agar and form tumors in nude mice. Because Plk expression has been shown to be high in various human tumors, we suggest that Plk may contribute to the promotion and/or progression of human cancers.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9177283     DOI: 10.1006/bbrc.1997.6633

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  86 in total

1.  Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.

Authors:  Juping Yuan; Mourad Sanhaji; Andrea Krämer; Wolfgang Reindl; Matthias Hofmann; Nina-Naomi Kreis; Brigitte Zimmer; Thorsten Berg; Klaus Strebhardt
Journal:  Am J Pathol       Date:  2011-08-10       Impact factor: 4.307

Review 2.  Mitosis as an anti-cancer drug target.

Authors:  Anna-Leena Salmela; Marko J Kallio
Journal:  Chromosoma       Date:  2013-06-18       Impact factor: 4.316

3.  Uncoupling anaphase-promoting complex/cyclosome activity from spindle assembly checkpoint control by deregulating polo-like kinase 1.

Authors:  Barbara C M van de Weerdt; Marcel A T M van Vugt; Catherine Lindon; Jos J W Kauw; Marieke J Rozendaal; Rob Klompmaker; Rob M F Wolthuis; René H Medema
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

4.  Calcium-dependent inhibition of polo-like kinase 3 activity by CIB1 in breast cancer cells.

Authors:  Meghna U Naik; Ngoc T Pham; Kristin Beebe; Wei Dai; Ulhas P Naik
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

Review 5.  Cdk1, Plks, Auroras, and Neks: the mitotic bodyguards.

Authors:  Patrick Salaun; Yoann Rannou; Claude Prigent
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

Review 6.  Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer.

Authors:  Steven L Warner; Bret J Stephens; Daniel D Von Hoff
Journal:  Curr Oncol Rep       Date:  2008-03       Impact factor: 5.075

7.  Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.

Authors:  Glen J Weiss; Gayle Jameson; Daniel D Von Hoff; Barbara Valsasina; Cristina Davite; Claudia Di Giulio; Francesco Fiorentini; Rachele Alzani; Patrizia Carpinelli; Alessandro Di Sanzo; Arturo Galvani; Antonella Isacchi; Ramesh K Ramanathan
Journal:  Invest New Drugs       Date:  2017-07-20       Impact factor: 3.850

8.  Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells.

Authors:  Xiaoqi Liu; Raymond L Erikson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

9.  Stimulation of polo-like kinase 3 mRNA decay by tristetraprolin.

Authors:  Thierry J Horner; Wi S Lai; Deborah J Stumpo; Perry J Blackshear
Journal:  Mol Cell Biol       Date:  2009-02-02       Impact factor: 4.272

10.  Elevated levels of the polo kinase Cdc5 override the Mec1/ATR checkpoint in budding yeast by acting at different steps of the signaling pathway.

Authors:  Roberto Antonio Donnianni; Matteo Ferrari; Federico Lazzaro; Michela Clerici; Benjamin Tamilselvan Nachimuthu; Paolo Plevani; Marco Muzi-Falconi; Achille Pellicioli
Journal:  PLoS Genet       Date:  2010-01-22       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.